Pulmonary Disease, Chronic Obstructive
Conditions
Brief summary
Tolerability, efficacy and handling of Berodual® Respimat® 20/50µg/dose solution for inhalation in patients with chronic obstructive airways disease in daily practice
Interventions
Sponsors
Boehringer Ingelheim
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Men and women presenting with symptoms of chronic obstructive pulmonary disease * Both previously untreated patients and patients treated previously with Berodual® or with other anti-obstructive respiratory tract agents may be included
Exclusion criteria
* Patients presenting with the general and specific contraindications listed in the Patient Information Leaflet and the Basic Product Information
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in overall severity rated on 3-point scale | up to 4 weeks |
| Change in reduction in breathlessness rated on a 4-point scale | up to 4 weeks |
| Change in restriction of activity due to breathlessness rated on a 4-point scale | up to 4 weeks |
| Number of awakening due to nocturnal breathlessness rated on 4-point scale | up to 4 weeks |
| Global assessment of efficacy by the patients rated on 5-point scale | after 4 weeks |
| Global assessment of efficacy by the investigator rated on 5-point scale | after 4 weeks |
| Number of patients with adverse drug reactions | up to 4 weeks |
Outcome results
None listed